When someone takes semaglutide, their appetite usually decreases
Disclosures: Henriette Kreimeyer: Nothing to Disclose, Carlos Gonzalez: Nothing to Disclose, Marcos Fondevila: Nothing to Disclose, Cynthia Hsu: Nothing to Disclose, Phillipp Hartmann: Nothing to Disclose, Xinlian Zhang: Nothing to Disclose, Peter Starkel: Nothing to Disclose, Francisco Bosques: Nothing to Disclose, Elizabeth Verna: Nothing to Disclose, Juan Abraldes: Gilead: Grant/Research Support, 89bio: Consultant, Boston Pharmaceuticals: Consultant, Novo Nordisk: Consultant, Boehringer Ingelheim: Consultant, Astra Zeneca: Consultant, Agomab: Consultant, Terumo: Speaking and Teaching, Cook: Grant/Research Support, Robert Brown: Gilead: Consultant, Intercept: Consultant, Abbvie: Consultant, Madrigal: Consultant, GSK: Consultant, eGenesis: Consultant, mirum: Consultant, Victor Vargas: Ipsen: Advisor, Orphalan: Speaking and Teaching, Jose Altamirano: Nothing to Disclose, Juan Caballeria: Nothing to Disclose, Debbie Shawcross: EnteroBiotix: Consultant, MRM Health: Advisor, Satellite Bio: Consultant, Norgine: Grant/Research Support, Apollo Therapeutics: Consultant, Genfit: Advisor, Alexandre LOUVET: Glaxo-Smith-Kline: Consultant, AbbVie: Speaking and Teaching, Gilead: Speaking and Teaching, Ipsen: Consultant, Astra-Zeneca: Speaking and Teaching, Michael Lucey: Nothing to Disclose, Philippe Mathurin: Nothing to Disclose, Guadalupe Garcia-Tsao: Nothing to Disclose, Ramon Bataller: Nothing to Disclose, Susan Mayo: Nothing to Disclose, David Gonzalez: Nothing to Disclose, Bernd Schnabl: Mabwell Therapeutics: Consultant, Ambys Medicines: Consultant, Surrozen: Consultant, Nterica Bio: Stock privately held company, Axial Biotherapeutics: Grant/Research Support, Prodigy Biotech: Grant/Research Support, CymaBay Therapeutics: Grant/Research Support, Intercept Pharmaceuticals: Grant/Research Support, ChromoLogic: Grant/Research Support 2069 NADH-REDUCTIVE STRESS LINKS THE ANTIOXIDANT CULLIN3-RING E3 LIGASE-NRF2 AXIS TO REGULATION OF HEPATIC STEATOSIS AND INSULIN SENSITIVITY Lijie Gu 1 Yanhong Du 1 Jianglei Chen 1 Mohammad Nazmul Hasan 1 Tiangang Li 1 , 1 University of Oklahoma Health Sciences Center Background Obesity and insulin resistance are major pathogenic drivers of metabolic dysfunction-associated steatotic liver disease (MASLD)
Although there is evidence that consumption of a high glucosinolate diet is linked with reduced incidence of chronic diseases, future large-scale placebo-controlled human trials including standardized glucosinolate supplements are needed
Although we cannot use raw peptide intensity values to compare the abundance of different protein species, it is notable that we could readily detect high numbers of peptides for NADPH-dependent carbonyl reductase 1 (CBR1) (supplementary files)
